You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
雪榕生物(300511.SZ):擬出資3000萬元設立全資子公司雪榕醫藥
格隆匯 01-10 17:53

格隆匯1月10日丨雪榕生物(300511.SZ)公佈,公司長期專注食用菌主業,致力於為消費者提供健康、安全、美味的食用菌產品,使消費者從中獲得快樂。公司非常看好食用菌的食藥用價值,已與中科中山藥物創新研究院簽署了《關於建設“中科中山藥物創新研究院雪榕多糖聯合實驗室”的協議書》,雙方共建“中科中山藥物創新研究院雪榕多糖聯合實驗室”,重點進行繡球菌等多糖活性機制及食用菌提取物的研究。

為了加速研發產品的商業化和項目推進,公司擬以自有資金出資3000萬元在上海設立全資子公司上海雪榕生物醫藥有限公司(名稱以市場監督管理局核准為準;簡稱“雪榕醫藥”),雪榕醫藥將聚焦具有升白抗腫瘤(提升白細胞,激活免疫細胞)、提升免疫力、抗氧化、抗病毒等功效的食用菌提取物的商品化,重點發力β-1,3葡聚糖、β-煙酰胺單核苷酸(NMN)等產品,首先切入功能食品、保健食品,同步發展食用菌提取物在抗腫瘤、提升免疫力等方面的新藥研發。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account